课题基金 / 基金详情

COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGEN

COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGEN
COBRE:确定医学研究发现:P2:自身抗原抗体产生的调节
批准号:
7382045
负责人:
Patrick Christopher Wilson
金额:
$26.19万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2007-06-30
关键词:

项目摘要

项目成果

Patrick Christopher Wilson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Vn4-34 immunoglobulin heavy chain genes, largely independent of the antibody D or J genes or the light chains, encode natural autoantibodies that recognize the i-antigen (polylactosamine [3Gal134GlcNAc13-],) and/or I-antigen (GlcNAc136-branched polylactosamine). The iI-antigen is a post-translational modification found on various glycoproteins and glycolipids in humans and on a number of pathogens. Neoplastic transformation and particular infections causing proliferations of VH4-34 + B cells can also cause pathological cold-agglutinin disease resulting in hemolytic anemia and the accumulation of antibodyerythrocyte complexes in small vessels. The VH4-34 gene has also been reported to play an increased role in various other autoimmune diseases including lupus, rheumatism, and multiple sclerosis. Despite the dangerous specificity encoded by VH4-34-utilizing antibodies, humans utilize VH4-34 to encode nearly 10% of their initial, antigen-na'fve repertoire. B cells utilizing VH4-34 are tightly regulated in T-dependent immune responses and are normally excluded from IgG antibody responses, further demonstrating the dangerous potential of this VH gone. It is important to define why humans have evolved to over-utilize the potentially pathological VH4-34 so profoundly in their early B cells only to exclude it from classic secondary immune responses and how these processes occur. In specific aim 1 the hypothesis is tested that the high prevalence of VH4-34 utilizing naive B cells in humans is due to an important role against a dangerous pathogen expressing glycans similar to human i/I antigens and that the protective immunity provided by this VH gone is more important than its dangerous potential. In specific aim 2, the molecular reason for VH4-34 overrepresentation in the na'fve B cell repertoire will be elucidated. In specific aim 3, a mouse model of VH4-34 immunity and tolerance will be generated and analyzed. The experiments proposed will benefit the specific disease processes associated with the VH4-34 gone and will provide many valuable insights into basic immunology topics including analysis of the delicate balance between immunity and autoimmunity that so often breaks down to cause devastating autoimmune diseases, control of V gene expression, immune evolution, and immunity to glycan antigen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploring the mechanistic basis for altered peripheral B cell selection in SLE
  • 批准号:
    8732775
  • 项目类别:
  • 资助金额:
    $30.81万
  • 财政年份:
    2014
  • 负责人:
    Patrick Christopher Wilson
  • 依托单位:
Monoclonal Antibody Technology Core
Monoclonal Antibody Technology Core
COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGEN
国内基金
海外基金
OSMI-4靶向O-糖基化调控PD-L1联合裂解OK-432协同治疗不完全消融后残存肝癌的机制研究
  • 批准号:
    JCZRLH202600261
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
mtlncRNA OK/SW-cl.16通过MEF2D-ND6通路介导肺腺癌顺铂耐药的机制研究
  • 批准号:
    --
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2022
  • 负责人:
    杜贺
  • 依托单位:
肺淋巴管肌瘤病类器官分析 OK432治疗乳糜胸的机制研究
  • 批准号:
    2020A151501294
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2020
  • 负责人:
    邱源
  • 依托单位:
OK-432联合PD-1单抗治疗肝癌射频消融后残存和远处转移瘤的机制及疗效研究
  • 批准号:
    82072041
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2020
  • 负责人:
    阚雪锋
  • 依托单位: